COMPUGEN LTD. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.15 USD | -2.71% |
|
+8.14% | +8.69% |
| 03-08 | Truist Securities Adjusts Price Target on Compugen to $5 From $4, Maintains Buy Rating | MT |
| 03-05 | Transcript : Compugen Ltd., Q4 2023 Earnings Call, Mar 05, 2024 |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 37.9M 52M | Sales 2025 * | 35.29M 48.41M | Capitalization | 198M 271M |
|---|---|---|---|---|---|
| Net income 2024 * | -13M -17.84M | Net income 2025 * | -29M -39.79M | EV / Sales 2024 * | 5.22 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 5.61 x |
| P/E ratio 2024 * |
-17
x | P/E ratio 2025 * |
-8.19
x | Employees | 68 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.62% |
More Fundamentals
* Assessed data
More news
Latest transcript on Compugen Ltd.
More recommendations
More press releases
| 1 day | -2.71% | ||
| 1 week | +8.14% | ||
| Current month | +11.50% | ||
| 1 month | -7.64% | ||
| 3 months | +0.56% | ||
| 6 months | +235.52% | ||
| Current year | +8.69% |
1 week
2.03
2.25
1 month
1.832.40
Current year
1.723.03
1 year
0.533.03
3 years
0.519.20
5 years
0.5119.90
10 years
0.5119.90
| Managers | Title | Age | Since |
|---|---|---|---|
Anat Cohen-Dayag
CEO | Chief Executive Officer | 57 | 01-12-31 |
Alberto Sessa
DFI | Director of Finance/CFO | 61 | 22-10-31 |
Eran Ophir
CTO | Chief Tech/Sci/R&D Officer | - | 14-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Paul Sekhri
CHM | Chairman | 65 | 17-10-01 |
Sanford Zweifach
BRD | Director/Board Member | 68 | 18-06-10 |
Gilead Halevy
BRD | Director/Board Member | 57 | 18-06-10 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-08 | 2.152 | -2.62% | 83 683 |
| 24-05-07 | 2.21 | +2.79% | 301,497 |
| 24-05-06 | 2.15 | +1.90% | 178,293 |
| 24-05-03 | 2.11 | -2.31% | 231,334 |
| 24-05-02 | 2.16 | +8.54% | 553,341 |
Delayed Quote Nasdaq, May 08, 2024 at 10:57 am
More quotes
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
Calendar
2024-05-20
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.21
USD
Average target price
5.333
USD
Spread / Average Target
+141.33%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +8.69% | 198M | |
| +22.59% | 46.4B | |
| -1.08% | 41.75B | |
| +47.98% | 41.37B | |
| -3.52% | 29.71B | |
| +10.30% | 26.01B | |
| -19.01% | 19.52B | |
| +30.53% | 12.43B | |
| +0.35% | 12.18B | |
| -0.65% | 12.13B |
- Stock Market
- Equities
- CGEN Stock